![Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia](https://oncodaily.com/pub/uploads/2023/07/Dr.-Hagop-Kantarjian-1280x720.jpeg)
Photo of Hagop Kantarjian from mdanderson.org
Mar 10, 2024, 20:49
Hagop Kantarjian: In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia
Hagop Kantarjian, a Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, recently posted on X:
“In this phase 2 study, a convenient, fully-oral regimen was effective and safe in an older/unfit population with acute myeloid leukemia. ”
Source: Hagop Kantarjian/X